Introduction
Cholesterol is taken into cells by Niemann-Pick C1-Like 1 (NPC1L1), which is a cholesterol transporter residing in the small intestinal epithelial cells, and then is incorporated into Apo-B48 to form chylomicrons, which are transported into the circulation via lymphatic vessels (Tomkin, 2008; Iqbal J and Hussain MM, 2009 ).
Ezetimibe, an inhibitor of NPC1L1, is known to suppress cholesterol intake via the intestine (Altmann et al., 2004; Garcia-Calvo et al., 2005) . This agent influences fatty acid supply to the body not only through suppression of cholesterol absorption but also by influencing the synthesis and secretion of chylomicrons (Bari et al., 2012) . It has been reported that the agent reduces postprandial hyperlipidemia (Yunoki et al., 2011) , improves insulin resistance, and reduces low-density lipoproteins (Tamaki et al., 2012) .
Non-alcoholic fatty liver disease (NAFLD) represents the hepatic manifestation of the metabolic syndrome, characterized by insulin resistance, dyslipidemia, and hypertension. The term NAFLD encompasses a broad spectrum of liver diseases ranging from simple steatosis to non-alcoholic steatohepatitis (NASH). Although simple steatosis usually follows a benign course, NASH is a progressive disease that can evolve into cirrhosis and hepatocarcinoma (Krawczyk et al., 2010; Smith and Adams, 2011) . It has been assumed that simple steatosis progresses stepwise to NASH as a result of excess generation of reactive oxygen species which trigger lipoperoxidation as well as mitochondrial dysfunction, leading to oxidative stress-induced liver tissue damage (Berson et al., 1998; Day and James, 1998; Koek et al., 2011) .
NAFLD patients often have iron deposition in the liver (George et al., 1998; Nelson et al., 2011) , which underscores the relationship between hepatic iron overload and tissue damage. Experiments in rodents have shown that iron overload This article has not been copyedited and formatted. The final version may differ from this version.
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JPET #203448 -7 -stimulates the synthesis of cholesterol (Graham et al., 2010) and reduces triglyceride levels (Kirsch et al., 2006) in the liver. In addition, several epidemiologic surveys have demonstrated that a correlation exists between hyperferritinemia and insulin resistance (Jiang et al., 2004; Jehn et al., 2004; Forouhi et al., 2007) . It has also been shown that mice fed a high-fat diet undergo sustained hepatic inflammation, which influences hepatic hepcidin expression, resulting in a reduction of the hepatic iron level (Chung et al., 2011) . These reports suggest the possibility that lipid metabolism interacts with iron metabolism. Bile duct ligation was found to reduce the hepatic iron level but pravastatin administration reversibly increased the level, affecting expression of iron metabolism-related genes in the rat (Kolouchova et al., 2011) . This report suggests the possibility that pravastatin, a cholesterol-lowering agent, may influence hepatic iron metabolism. Accordingly, we explored the effects of ezetimibe, which corrects hypercholesterolemia by mechanisms different from those of statins, on iron metabolism in the liver as well as the duodenum of mice fed either a high-fat or a control diet. It was found that ezetimibe influenced the hepatic iron level and expression of iron metabolism-related genes, and thus we proceeded to explore the effects of ezetimibe on iron metabolism in mice that ingested excessive amounts of iron.
the control plus iron group (CI), 2) the same diet as the CI group for 12 weeks (iron;
21.1mg/day), but ezetimibe (0.3 mg/day) was added for the last four weeks, similarly to Experiment 1; the control plus iron plus ezetimibe group (CIE), 3) a high-fat diet for 6 weeks followed by a high-fat diet containing carbonyl iron (24.3mg/day) for 6 weeks;
the high-fat diet plus iron group (HI), 4) the same diet as the HI group for 12 weeks (iron; 22.7mg/day), but ezetimibe (0.3 mg/day) was added for the last four weeks; the high-fat diet plus iron plus ezetimibe group (HIE). The composition of the control and experimental diets is shown in Supplemental Table. As carbonyl iron and ezetimibe were fine powder, ezetimibe and/or carbonyl iron were thoroughly mixed with other compositions of each diet using a food mixer to obtain the desired concentrations in the feed. The doses of ezetimibe and carbonyl iron were chosen with reference to previous reports (Zheng et al., 2008; Paraskevas et al., 2011) . Individual body weights and food intake were recorded once or twice a week, respectively. Based on these data, the amount of ezetimibe and carbonyl iron mixed in diets was adjusted each time to administer approximately same total amount of ezetimibe and/or carbonyl iron between groups when diets were prepared. After 12 weeks, food was removed two hours prior to collecting tissues and blood samples were collected by heart puncture after anesthesia, and livers and duodenum were harvested and stored at -80°C until use. A mouse of the HI group was dropped out of Experiment 2 because he was injured and extremely lost his weight. Studies were approved by Quantification of serum biochemical markers , hepatic lipids, and hepatic iron.
Serum biochemical markers were quantified using biochemistry autoanalyzer Labospect 008 (Hitach High-Technologies Corporation, Ibaragi, Japan). Liver lipid content was extracted according to the method of previous report (Folch et al., 1957) .
Hepatic cholesterol and triglyceride concentrations were determined by standard enzymatic-colorimetric assays using commercially available kits (Wako Pure Chemical Industries, Osaka, Japan). Hepatic iron concentrations were quantified by the method of previous report (Torrance and Bothwell, 1980) .
RNA isolation and real-time PCR.
Total RNA was isolated using TRIzol reagent (Life Technologies, Tokyo, Japan) according to the manufacturer's protocol. The concentration of total RNA in each sample was quantified spectrophotometrically at 260nm. The mRNA expression of lipid and iron metabolism-related genes and 18s rRNA were quantified by SYBR real-time polymerase chain reaction (PCR) (SYBR Premix Ex Taq ; Takara bio Inc. , Shiga, Japan). Primers were used from previous reports (Tanaka et al., 2012; Dupic et al., 2002; Wallace et al., 2005; Vokurka et al., 2006; Lin et al., 2006; Wang et al., 2009; Kiessling et al., 2009 receptor were increased more in CE than C, and in HE than H (Table 1) .
mRNA expression of fatty acid-related genes in liver. Srebp-1c was not changed between groups. After 12 weeks, fatty acid synthase (Fas) was increased in CE compared to C. Acyl-CoA oxidase 1 (Acox1) was increased more in CE than C, and in HE than H (Table 1) .
Serum iron and hepatic iron concentrations.
There was no significant difference in the serum iron levels, unsaturated iron binding capacity (UIBC), and transferrin saturation (transferrin %) among the groups. Hepatic iron concentrations were higher in the HE group compared to the H group, whereas there was no significant difference between the C group and the CE group ( Fig. 1 ).
mRNA expression of iron metabolism-related genes in liver. Hepatic mRNA expression of iron metabolism related genes, including transferrin receptor1(Tfr1), divalent metal transporter1(DMT1), ferritinH, ferritinL, hepcidin, hemojuvelin, neogenin, and transferrin receptor2 (Tfr2) were increased in the CE group compared to the C group, and in the HE group compared to the H group. Furthermore, ferritinH, ferroportin1, hepcidin, neogenin, and Tfr2 mRNA levels were increased in the HE group compared to the CE group (Fig. 2 ).
mRNA expression of iron metabolism-related genes in duodenum. In duodenum, the mRNA expression of iron metabolism-related genes, including DMT1, FerritinH, and hephaestin were increased in the CE group compared to the C group (Table 2) . No change was observed in iron metabolism-related genes expression between the H group and the HE group. 
Experiment 2
Body weight, liver weight, liver weight to body weight, and serum and hepatic lipid profiles. After 12 weeks, HIE tended to gain less body weight compared to HI.
Liver weight was lower in HIE than HI as well as CIE. The final ratio of liver weight to body weight was lower in HIE than HI. Similar to Experiment 1, the administration of ezetimibe did not alter serum total cholesterol concentrations in any group. However, ezetimibe decreased HDL-cholesterol levels in the high-fat diet groups (data not shown). At 12 weeks, serum triglycerides were lower in the CIE and HI groups compared to the CI group. Hepatic total cholesterol was decreased in the CIE group compared to the CI group. Hepatic triglycerides were decreased in the HIE group compared to the HI group (Table 3) .
Serum ALT and ALP. Similar to the results of Experiment 1, serum ALT and ALP
were not statistically significant differences between groups (data not shown).
mRNA expression of cholesterol-related genes in liver. At 12 weeks, Srebp2 mRNA expression was increased more in HI than C, HIE than CIE, and in HIE than HI.
After 12 weeks, HMGCoAR mRNA was increased in the HIE group compared to the CIE group and tended to be increased in the HIE group compared to the HI group.
The mRNA expression of Ldl receptor was not changed in any group (Table 3) .
mRNA expression of fatty acid-related genes in liver. Srebp-1c was not changed between groups. At 12 weeks, Fas mRNA was not changed in any group, but the mRNA expression of Acox1 was increased in the HI group compared to the CI (Table 3) .
Serum iron and hepatic iron concentrations. After 12 weeks, serum iron concentrations, UIBC, and transferrin % were not changed among the groups. At 12 weeks, hepatic iron concentrations were higher in the HIE group compared to the HI group, whereas there was no significant difference between the CI group and the CIE group. Furthermore, hepatic iron levels were higher in HI than CI, and in HIE than CIE (Fig. 3 ).
mRNA expression of iron metabolism-related genes in liver. There was no significant difference in any mRNA expression of iron metabolism-related genes in liver between the CI group and the CIE group. However, hepatic mRNA expression of ferritinL and hepcidin were increased in the HIE group compared to the HI group.
The mRNA expression of hepcidin and Tfr2 were increased in the HI group compared to the CI group. Ferritin H, ferritin L, ferroportin1, hepcidin and Tfr2 mRNA levels were increased in the HIE group compared to in the CIE group (Fig. 4) .
mRNA expression of iron metabolism-related genes in duodenum. In duodenum, only ferritin L mRNA expression was increased in the HIE group compared to the CIE group (Table 4) . No change was observed in other iron metabolism-related genes expression among the groups.
This article has not been copyedited and formatted. The final version may differ from this version. Since several studies have indicated that a relationship exists between lipid metabolism and iron metabolism, we assumed that a cholesterol-lowering agent could potentially influence iron metabolism. The current study reported for the first time that ezetimibe, an inhibitor of cholesterol transport, affected iron metabolism.
Although the dosage of ezetimibe was determined with reference to previous reports (5mg/Kg/day to 10mg/Kg/day) (Zheng et al., 2008; Paraskevas et al., 2011) , this dose was much higher compared to the ordinary dose for humans. Thus, further studies should be conducted to clarify whether ezetimibe increases hepatic iron in humans.
In Experiment 1, the hepatic iron level did not differ significantly between C and CE, whereas it was higher in the HE group versus the H group. Regarding expression of genes related to hepatic iron metabolism, the levels of Tfr1, Tfr2, DMT1, ferritin H, and ferritin L mRNA were increased by ezetimibe administration in both the control-diet groups and high-fat diet groups. These results suggest that ezetimibe stimulated iron uptake into the liver in the control-diet groups and high-fat diet groups and it also enhanced mRNA expression of hepcidin, hemojuvelin, and neogenin. contributed to an increase in hepatic iron levels in Experiment 1. In the duodenum, mRNA levels of DMT1, ferritin H and hephaestin were more significantly elevated in CE than C, while DMT1 mRNA expression tended to be increased in HE compared to H. It was therefore suggested that ezetimibe enhanced duodenal iron absorption.
In Experiment 2, we explored the effects of ezetimibe on iron metabolism under conditions of iron overload. Whereas hepatic iron levels did not differ between CI and CIE, the levels were higher in HIE than HI similar to the effects observed in mRNA nor Tfr2 mRNA expression was enhanced by ezetimibe administration in that experiment. In the duodenum, there was no change in the expression of iron metabolism-related genes in the iron-overload experiment. An excessive amount of iron administered orally into the duodenum seemed to mitigate the effect of ezetimibe on those genes. Experiment 2 showed that hepatic iron levels were higher in HI than CI, and higher in HIE than CIE. Furthermore, the expression of mRNA for ferritin H/L, ferroportin 1, hepcidin, and Tfr2 was enhanced to a significantly greater degree in HIE than CIE. It was therefore assumed that ezetimibe-induced hepatic iron deposition was greater in the high-fat diet groups than the control-diet groups in Experiment 2, similarly to Experiment 1. Tfr2 mRNA expression, but not Tfr1mRNA expression, was enhanced by high-fat diet feeding. Under conditions of high-fat diet feeding with iron overload, Tfr2 may play a more important role than Tfr1 in increasing hepatic iron levels (Fleming et al., 2000; Tsuchiya et al., 2010a) . It was demonstrated in both Experiments 1 and 2 that ezetimibe increased hepatic iron levels in mice fed a high-fat diet in the presence or absence of hepatic iron overload. Recent study showed that a high-fat diet increased hepatic iron and Tfr2 mRNA expression in rats (Ahmed and including saturated fatty acids, and/or increased hepatic lipid accumulation may be involved in the effects of ezetimibe on iron metabolism, leading to a synergistic increase in hepatic iron levels. In our study, mice were fed a high-fat diet for six weeks and then were fed either a high-fat diet or a high-fat diet with iron until 8 weeks.
At 8 weeks, hepatic steatosis was considered enough to be developed. Thus, it might be interesting to determine whether ezetimibe administration on a control diet increases hepatic iron concentrations in genetic obese mice with hepatic steatosis.
If ezetimibe could enhance hepatic iron levels in these mice, hepatic steatosis rather than the components of the high-fat diet would be involved in the effects of ezetimibe on the regulation of iron metabolism genes. Indeed, it is not known why the high-fat diet or steatosis modulates the effects of ezetimibe on iron metabolism. Previous studies showed that multidrug resistance (Mdr) 1 and multidrug resistance-associated protein (Mrp) 2 deficiency increased serum and hepatic ezetimibe glucuronide levels (Oswald et al., 2006; Oswald et al., 2010) . Recent study demonstrated that serum levels of ezetimbe glucuronide were increased after either oral or intravenous administration of ezetimibe in rats fed a methionine-and choline-deficient diet (Hardwick et al., 2012) . Previous report showed that Mrp2 mRNA levels were reduced in livers of male rats fed a high-fat diet (Lickteig et al., 2007) . Furthermore, Mrp2 protein expression was decreased in fatty liver of the obese Zucker rats, an established model for NAFLD (Geier et al., 2005) . Taken together, these data suggest that the high-fat diet or fatty liver-induced changes in efflux transporter expression may affect the disposition and pharmacological effects of ezetimibe.
Thus, it might be of interest to determine whether serum and hepatic levels of ezetimibe and hepatic Mrp2 expression are different between the control-diet groups and the high-fat diet groups in our study.
In regard to iron excretion, ferroportin1, which is the only iron exporter that has been identified to date, plays a crucial role. Ferroportin1 was originally identified as an iron exporter that transports iron from the duodenal epithelial cells to the circulation.
The circulating peptide hormone hepcidin inhibits cellular iron efflux by binding to duodenal ferroportin1. Previous studies demonstrated that hepatic ferroportin1 is also down-regulated by hepcidin produced by hepatocytes (Aigner et al., 2008; Ramey et al., 2010) . In Experiment 1, however, the present study showed that hepatic ferroportin1 mRNA expression was enhanced despite an increase in hepcidin mRNA, which is consistent with another report (Theurl et al., 2005) . Although the reason for this discrepancy is not clear, it may be explained by between the species studied. Ezetimibe stimulated hepatic iron uptake into the liver, leading to increased hepatic iron levels in our current experiments. It can be inferred that hepatic ferroportin1 mRNA expression was induced in a compensatory manner to maintain a constant level of hepatic iron.
In terms of hepatic lipid metabolism and deposition, feeding a high-fat diet regard to cholesterol metabolism, iron supplemented control diet (CI group) increased hepatic cholesterol levels, in agreement with the aforementioned report (Graham et al., 2010) . Besides, ezetimibe decreased hepatic cholesterol in the only control-diet groups. Conversely, neither ezetimibe nor iron reduced hepatic cholesterol in the high-fat diet groups. Summary of high-fat diet with ezetimibe and/or iron-induced changes in hepatic triglyceride, cholesterol, and iron levels was shown in Table 5 .
In conclusion, ezetimibe tended to increase DMT1 mRNA expression in the duodenum of mice fed a high-fat diet and significantly enhanced hepatic Tfr1 mRNA expression, leading to an increase in hepatic iron levels. Because hepatic iron levels were not increased in mice fed a control diet, it was possible that some components of the high-fat diet and/or the steatosis induced by high-fat diet feeding modified the effects of ezetimibe on iron metabolism in the liver. Data are presented as mean ± S.E.M. (each group, n = 6 animals). C, the control group; CE, the control plus ezetimibe group; H, the high-fat diet group; HE, the high-fat diet plus ezetimibe group. * represents statistically significant difference (p < 0.05) between H and HE. Data are presented as mean ± S.E.M. (each group, n = 6 animals). C, the control group; CE, the control plus ezetimibe group; H, the high-fat diet group; HE, the high-fat diet plus ezetimibe group. * represents statistically significant difference (p < 0.05) between two groups as indicated by connected lines in figure; ** similarly represent a statistically significant difference (p < 0.01) between two groups. Data are presented as mean ± S.E.M. (each group, n = 5 or 6 animals). CI, the control plus iron group; CIE, the control plus iron plus ezetimibe group; HI, the high-fat diet plus iron group; HIE, the high-fat diet plus iron plus ezetimibe group. Data are presented as mean ± S.E.M. (each group, n = 5 or 6 animals). CI, the control plus iron group; CIE, the control plus iron plus ezetimibe group; HI, the high-fat diet plus iron group; HIE, the high-fat diet plus iron plus ezetimibe group. * represents statistically significant difference (p < 0.05) between two groups as indicated by connected lines in figure; ** similarly represent a statistically significant difference (p < 0.01) between two groups. Therapeutics. Abbreviations: C, the control group; CE, the control plus ezetimibe group; H, the high-fat diet group; HE, the high-fat diet plus ezetimibe group; CI, the control plus iron group; CIE, the control plus iron plus ezetimibe group; HI, the high-fat diet plus iron group; HIE, the high-fat diet plus iron plus ezetimibe group. 
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